An anchoring agent abrasive mixing device, comprising a mixing barrel, a stirring mechanism is arranged in the mixing barrel, a screw rod is installed in the mixing barrel against the wall, and a driving motor for driving the rotation of the screw rod is arranged on the mixing barrel, so that the The screw comprises a first threaded part on the upper part and a second threaded part on the lower part, the thread directions of the first threaded part and the second threaded part are opposite, and the first threaded part and the second threaded part are symmetrically sleeved with The nut sleeve is provided with an annular scraper adapted to the inner wall of the mixing barrel, and the rotation of the screw makes the nut sleeves located on the first threaded part and the second threaded part move toward each other or relatively deviate from each other. The movement will drive the annular scraper to scrape off the material on the inner wall of the mixing barrel, so as to prevent the material from accumulating on the inner wall of the mixing barrel for a long time, and ensure the cleaning of the mixing barrel. Castable Anchor,Abrasive Anchors,Anchors For Castable,Thread Stud Anchors Puyu kiln technology (jiangsu) CO.,LTD , https://www.anchorpy.com
Zhang Jianguo believes that in the region to strengthen the convergence of the industry, the middle and lower reaches and the division of labor between each other to achieve the organic combination of various elements to form a complete industrial chain, is to avoid inter-regional industrial homogenization, vicious competition, to achieve regional complementarity A win-win situation will increase the internal demand for the overall competitiveness of the industry.
It is understood that the bio-industry has become the fastest-growing industry and its growth rate is 10 times the average growth rate of the world economy. Statistics show that by 2020, the proportion of biomedicine in global medicine will exceed 30%.
At present, Beijing, Tianjin and Hebei have all determined biopharmaceuticals as the focus of industrial development. However, compared with their counterparts at home and abroad, the general structure of the Beijing-Tianjin-Hebei biopharmaceutical industry is irrational. There are numerous pharmaceutical companies, but the scale is generally small, there are not many giant biopharmaceutical companies, and the international competitiveness is weak. For example, in 2009, the annual sales revenue of Amgen, a US modern biopharmaceutical company, amounted to 13.4 billion U.S. dollars. The annual sales revenue of Shijiazhuang Pharmaceutical Group, the largest pharmaceutical company in Beijing, Tianjin and Hebei, was only 10.6 billion yuan. Another example is that the traditional Chinese medicine industry is a traditional advantageous industry in the three places, but the level of development of modern Chinese medicine is far from that of Japan and South Korea. In addition, like the Yangtze River Delta region in recent years, the biopharmaceutical industry has developed rapidly. The annual output value of the Jiangsu biopharmaceutical industry alone is tens of billions more than the sum of the three places in Beijing, Tianjin and Hebei.
Zhang Jianguo believes that “Beijing-Tianjin-Hebei has a number of pharmaceutical products and production bases with the world's largest production volume, leading international technology, and leading domestic scale; it has gathered a number of pharmaceutical companies that are influential and competitive in the country; they all have strong R&D strength; there is a good foundation for promoting the integration of Beijing-Tianjin-Hebei biopharmaceutical industry chain.â€
However, at present, there is more than enough cooperation in the three places, and poor coordination and support. Although Beijing-Tianjin-Hebei has strong scientific and technological strength in the field of biomedicine, the three places have advantages in R&D production and sales of traditional Chinese medicine, chemical drugs, and biological drugs, and they have strong complementarity in the pharmaceutical industry chain and value chain, but they lack a deep level. High level of interaction and cooperation. Due to institutional reasons, regions, departments, and industries are separated from each other, enterprises are facing difficulties in “scientific and technological innovation†and “transforming achievements†in universities and research institutes. The phenomenon of repeated input and low-level competition still occurs. The Beijing-Tianjin-Hebei region has shared the conditions for the sharing of technological resources, the development of development forces, the application of new technologies, and the rapid advancement of industrialization.
In response, Zhang Jianguo suggested that the Beijing-Tianjin-Hebei biopharmaceutical industry must rapidly improve the overall industrial competitiveness, it must continue to innovate breakthroughs in the mode of thinking, organizational forms, service methods. Break through the barriers of thinking in the administrative region, strengthen the awareness of the Beijing-Tianjin-Hebei metropolitan area, change each of them into individual prisons for the inter-regional "cluster" cooperation with the advantage of benefits as the link, and the regional services that become administrative barriers to accelerate the formation of Beijing. Tianjin-based biomedical industry chain has rapidly realized industrialization of regional services.
He also put forward five specific recommendations: First, the relevant national departments took the lead in compiling the Beijing-Tianjin-Hebei biopharmaceutical industry development plan; the second was to establish cooperative mechanisms for the realization of win-win cooperation among enterprises, scientific research institutions, universities and research personnel in the three regions of Beijing, Tianjin and Hebei; To establish a mechanism for the sharing of resources of the Beijing, Tianjin, and Hebei biological medicine industry, strengthen communication and public platform construction, and jointly build and share the large-scale scientific instrument sharing platform networks in three provinces and cities; Fourth, to jointly build a market centered on bio-pharmaceutical industry innovation activities; The strategic alliance for technological innovation in the biomedicine industry, through alliances, has broken through the core technologies of industrial development and formed important industrial technological standards to accelerate the enhancement of the competitiveness of Beijing-Tianjin-Hebei biomedical industry.
“The Beijing-Tianjin-Hebei region has a good foundation and obvious advantages in accelerating the development of the biopharmaceutical industry. There is ample room for cooperation and the biopharmaceutical industry in the three places is in urgent need of development.†Zhang Jianguo, deputy inspector of the Policy Research Office of the Hebei Provincial Party Committee, said in an interview this week.